Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort

Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort

Carmen Rossi et al, Journal of Hepotology Nov 2018 (2019)

Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort

English English
Website Website
Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C virus (HCV) elimination. However, reinfection among people who inject drugs (PWID) may hamper elimination targets. Therefore, we estimated HCV reinfection rates among DAA-treated individuals, including PWID.
View in new window
More details
Click here to open "Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort" in new browser window
In partnership with:
ISFF
FUAS
Correlation Network